# Bimekizumab: Ein Medikament mit Langzeitwirkung bei Schuppenflechten-Arthritis Forscher haben gute Nachrichten für Menschen mit Schuppenflechten-Arthritis. Das Medikament Bimekizumab wirkt auch nach drei Jahren noch zuverlässig[1]. Es greift zwei Stoffe des Immunsystems an, die bei der Erkrankung Probleme verursachen. In zwei großen Studien testeten Ärzte das Medikament bei Menschen ohne vorherige Biologika-Behandlung und bei Menschen, deren alte Medikamente nicht halfen[1]. Die Patienten be

Originaltitel: Mendelian randomization studies in atopic dermatitis: causal insights across omics layers Link zur Quelle

Originaltitel: Association between SARC-F as a self-report screening tool for sarcopenia and muscle strength, physical performance, daily activity, patient-reported outcomes and body composition in patients with spondyloarthritis. Link zur Quelle

Trial number: 2023-506333-29-00 Overall trial status: Ongoing, recruiting Trial title: A phase 3B exploratory multicenter open-label study to evaluate the effect of bimekizumab on gene expression biomarkers in study participants with moderate to severe plaque psoriasis. Medical conditions: Psoriatic arthritis, Moderate to Severe Plaque Psoriasis Status in each country: Poland:Ongoing, recruiting, Germany:Ongoing, recruiting Trial phase: Phase III and phase IV (Integrated) Therapeutic Areas

Trial number: 2023-506296-97-00 Overall trial status: Ongoing, recruiting Trial title: A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis Medical conditions: Moderate to Severe Plaque Psoriasis Status in each country: Germany:Ongoing, recruiting, Romania:Authorised, recruiting, Italy:Ongoing, recruiting

Trial number: 2023-507415-35-00 Overall trial status: Ongoing, recruitment ended Trial title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1) Medical conditions: Psoriatic Arthritis Status in each country: Czechia:Ended, Germany:Ended, Estonia:Ended, Spain:Ended, Slovakia:Ongoing, recruitment ended, Italy:Ended, Poland:Ended Trial phase: Ther

Psoriasis is a chronic immune-mediated disease with global prevalence of 2-3% that is associated with significantly reduced quality of life (QoL) and worsened mental health. Despite this, there is a lack of research in African psoriasis populations, with no modern epidemiological studies conducted in Kenya to examine these factors. This study aims to identify demographic and clinical features associated with dermatology-related QoL and mental health among psoriasis patients enrolled in the newly

Abstract Background Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real-world practice remains unclear. Objectives To evaluate

Introduction The rising incidence of inflammatory skin diseases, including psoriasis, has necessitated new treatment approaches. This paper focuses on the development of a hibiscetin-impregnated nanogel that reduces the severity of skin inflammation.Methods Imiquimod (IMQ) was used to induce psoriasis-like inflammation in animal models, and the nanogel's worthiness was compared. Nanogel was prepared in different concentrations of hibiscetin, namely F1 (1) and F2 (2), and characterized in terms o